Precision medicine can slow cancer growth…….. September 2016
A clinical trial has found that precision medicine – or tailoring treatment for individual patients – can delay the time it takes for a tumour to grow back in some types of advanced cancer. This trial took place at Gustave Roussy Cancer Campus in Paris and was presented at the Molecular Analysis for Personalised Therapy (MAP) conference.
Patients involved in the trial had different types of advanced cancer including lung, breast, head and neck, prostate, bladder, bowel, and stomach cancer. The patients involved had no other treatment options and had already tried at least three other cancer therapies.
In the trial, the patients had their genes mapped and treatment tailored. 199 out of 1110 patients had approximately 30 per cent longer before their cancer started growing again compared to other treatments they had tried in the past.
The advantage of this approach is that it is not just for one type of cancer and many patients may be able to benefit in the future.
Dr Rowena Sharpe, head of precision medicine at Cancer Research UK, said: “This is an exciting time for precision medicine and personalised treatment. It’s fantastic to see continued effort going into this area and it’s important that we make the most of the data that we already have. The MAP meeting brings together expertise from across the globe to find the best ways to improve precision medicine programmes for cancer patients.”
For more information, see Cancer Research UK’s article here